GALT Galectin Therapeutics Inc

Price (delayed)

$4.30

Market cap

$245.77M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.41

Enterprise value

$218.63M

Sector: Healthcare
Industry: Biotechnology

Highlights

The company's net income has shrunk by 77% YoY and by 13% QoQ
Galectin Therapeutics's quick ratio has shrunk by 70% YoY and by 62% QoQ

Key stats

What are the main financial stats of GALT
Market
Shares outstanding
57.16M
Market cap
$245.77M
Enterprise value
$218.63M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
10.92
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$23.38M
EBITDA
-$23.34M
Free cash flow
-$20.6M
Per share
EPS
-$0.41
Free cash flow per share
-$0.36
Book value per share
$0.39
Revenue per share
$0
TBVPS
$0.52
Balance sheet
Total assets
$29.6M
Total liabilities
$5.41M
Debt
$0
Equity
$22.47M
Working capital
$24.07M
Liquidity
Debt to equity
0
Current ratio
5.46
Quick ratio
5.03
Net debt/EBITDA
1.16
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-63.3%
Return on equity
-73.4%
Return on invested capital
N/A
Return on capital employed
-96.6%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

GALT stock price

How has the Galectin Therapeutics stock price performed over time
Intraday
2.14%
1 week
7.5%
1 month
82.2%
1 year
64.75%
YTD
91.96%
QTD
98.16%

Financial performance

How have Galectin Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$23.44M
Net income
-$23.47M
Gross margin
N/A
Net margin
N/A
The company's net income has shrunk by 77% YoY and by 13% QoQ
The operating income has dropped by 74% year-on-year and by 13% since the previous quarter

Growth

What is Galectin Therapeutics's growth rate over time

Valuation

What is Galectin Therapeutics stock price valuation
P/E
N/A
P/B
10.92
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Galectin Therapeutics's EPS has decreased by 5% QoQ and by 5% YoY
The P/B is 132% above the last 4 quarters average of 4.6 but 60% below the 5-year quarterly average of 26.7
GALT's equity is down by 49% year-on-year and by 25% since the previous quarter

Efficiency

How efficient is Galectin Therapeutics business performance
Galectin Therapeutics's ROE has decreased by 33% YoY and by 32% from the previous quarter
The ROA has contracted by 27% from the previous quarter and by 26% YoY

Dividends

What is GALT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for GALT.

Financial health

How did Galectin Therapeutics financials performed over time
The total liabilities has soared by 116% from the previous quarter and by 88% YoY
Galectin Therapeutics's quick ratio has shrunk by 70% YoY and by 62% QoQ
The debt is 100% less than the equity
GALT's equity is down by 49% year-on-year and by 25% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.